Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adamis Pharmaceuticals Corporation    ADMP

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

ADAMIS PHARMACEUTICALS CORP : Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)

09/08/2020 | 05:23pm EST

Item 3.02 Unregistered Sales of Equity Securities

The information provided under Item 5.03 below concerning the filing by Adamis Pharmaceuticals Corporation (the "Company") of an amendment to the Company's restated certificate of incorporation, and the information provided under Items 1.01 and 3.02 of the Company's Report on Form 8-K filed with the Securities and Exchange Commission (the "Commission") on June 16, 2020, concerning the issuance of 1,000,000 shares of Series B Convertible Preferred Stock (the "Series B Preferred") to Matrix Biomed, Inc. ("Matrix), is incorporated herein by reference. As a result of the filing of such amendment, effective September 4, 2020, the 1,000,000 shares of Series B Preferred previously issued to Matrix automatically converted into 1,000,000 shares of common stock of the Company. The shares of Series B Preferred, and the shares of common stock issued upon conversion of the Series B Preferred, were issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and/or Regulation D under the Securities Act. Matrix represented that it was an accredited investor, as defined in Rule 501 of Regulation D, and that it was acquiring the securities for its own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the Act.

Item 3.03. Material Modification to Rights of Security Holders.

The information provided under Item 5.03 below with respect to the Company's filing of a Certificate of Amendment of the Company's Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company's common stock from 100,000,000 to 200,000,000, is incorporated herein by reference.

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal

           Year.



On September 3, 2020, the Company filed a Certificate of Amendment of the Company's Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company's common stock from 100,000,000 to 200,000,000 (the "Amendment"). The Company's stockholders approved the Amendment on September 3, 2020, which had previously been approved by the board of directors of the Company, at the Company's 2020 annual meeting of stockholders as described under Item 5.07 of the Company's Report on Form 8-K filed with the Commission on September 8, 2020.

Item 9.01 Financial Statements and Exhibits




Exhibit No. Description
3.1           Certificate of Amendment to the Restated Certificate of
            Incorporation of the Company.




                                       2

© Edgar Online, source Glimpses

All news about ADAMIS PHARMACEUTICALS CORPORATION
12/01ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
12/01Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response ..
GL
11/17ADAMIS PHARMACEUTICALS : Receives a Complete Response Letter from the FDA Regard..
AQ
11/16ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
11/16ADAMIS PHARMACEUTICALS : Receives a Complete Response Letter from the FDA Regard..
AQ
11/16Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regar..
GL
11/09ADAMIS : 3Q Earnings Snapshot
AQ
11/09ADAMIS PHARMACEUTICALS : Announces Third Quarter 2020 Financial Results and Busi..
AQ
11/09Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Bus..
GL
11/09ADAMIS PHARMACEUTICALS CORP : Results of Operations and Financial Condition (for..
AQ
More news
Financials (USD)
Sales 2020 18,3 M - -
Net income 2020 -33,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -1,19x
Yield 2020 -
Capitalization 49,5 M 49,5 M -
Capi. / Sales 2020 2,71x
Capi. / Sales 2021 1,95x
Nbr of Employees 151
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price
Last Close Price 0,53 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Dennis J. Carlo President, Chief Executive Officer & Director
Richard C. Williams Chairman
Karen K. Daniels Vice President-Operations
Robert O. Hopkins Chief Financial Officer, Secretary & VP-Finance
Ronald B. Moss Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAMIS PHARMACEUTICALS CORPORATION-24.60%49
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.59%284 650
PFIZER, INC.6.17%219 056
MERCK & CO., INC.-10.34%206 324
NOVARTIS AG-11.46%205 415